MMR-varicella zoster virus vaccine - GlaxoSmithKline

Drug Profile

MMR-varicella zoster virus vaccine - GlaxoSmithKline

Alternative Names: GSK-208136; Priorix-Tetra; PriorixTetra

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Measles vaccines; Rubella vaccines; Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella; Varicella zoster virus infections

Most Recent Events

  • 06 Oct 2016 No development reported - Phase-III for Measles (Prevention) in South Korea (SC)
  • 06 Oct 2016 No development reported - Phase-III for Mumps (Prevention) in South Korea (SC)
  • 06 Oct 2016 No development reported - Phase-III for Rubella (Prevention) in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top